Diabetes

Diabetes cases in the US among those younger than age 20 years, if left unchecked, are projected to increase by more than 600% by 2060, according to new projections.

A global prevalence of osteoporosis among persons with T2D of more than 25% calls for greater focus on screening for and managing the bone loss disease in this population.

Optimal glycemic control (less than 7%) in participants from the Look AHEAD trial was associated with smaller increases in frailty index score vs poorer control over the 8-year study period.

Find a compact sampling of 2022 research on type 2 diabetes and its treatment reviewed on Patient Care, chosen by the editorial staff.

Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.

About one-quarter of children with T2D are not obese, according to a meta-analysis, making comprehensive screening essential in the population.

The Dexcom G7 continuous glucose monitoring system provides an overall MARD of 8.2%, the highest of any FDA-cleared CGM, the company says.

Empagliflozin is the first SGLT-2 inhibitor to demonstrate a statistically significant reduction in HbA1c in children and adolescents with type 2 diabetes.

An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.

Teplizumab, an anti-CD3 monoclonal antibody, delayed the median onset of stage 3 T1D by approximately 2 years compared to placebo in a pivotal clinical trial.

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

Your daily dose of clinical news you may have missed.

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.